Comparison of homocysteinemia and MTHFR 677CT polymorphism with Framingham Coronary Heart Risk Score.
The Framingham Coronary Heart Disease Risk Score is an important clinical tool. The aim of this cross-sectional study was to compare plasma homocysteine levels and polymorphism 677CT MTHFR with this score to determine the utility of these new biomarkers in clinical practice. Plasma homocysteine levels determined by chemiluminescence and polymorphism 677CT MTHFR, detected by PCR-RFLP, were compared with Framingham coronary risk score in a cross-sectional survey on 68 men and 165 women. Coronary heart disease risk augmented with an increase in the quartile of plasma homocysteine. In the 2nd, 3rd and 4th quartile of plasma homocysteine, men showed significantly (P<0.001) higher risk than women. For the highest quartile of plasma homocysteine, OR of high-risk (10-year risk≥20%) compared with the lowest quartile was 17.45 (95% CI: 5.79-52.01). Frequencies of CT and TT genotype and T allele were not over-represented in the individuals with score≥10%. The higher plasma homocysteine concentrations in individuals with score≥10% with respect to those with low risk (P<0.005 and P<0.001) were not due to the presence of T allele. The T allele (CT+TT genotypes) of the MTHFR C677T polymorphism was not significantly associated with an increased risk of coronary disease (OR=1.09, 95% CI=0.50-2.39, P=0.844). The present study demonstrated an association between plasma homocysteine levels and the severity of coronary heart disease estimated with the Framingham coronary risk score, and this association appeared to be independent on the genotype of MTHFR. We postulate that plasma homocysteine is effective enough, considered even in isolation.